Novamind Granted DEA Licenses for Psilocybin Research

Novamind Inc. (NM : CSE) (NVMDF: OTCQB) (HN2: FSE) Is One of America’s leading providers of psychedelic medicine. Key Highlights: Developing a national clinic network to administer psychedelic medicine pending the FDA approval of MDMA in 2023 and psilocybin in 2025 6 clinics open, 2 clinics coming soon Facilitated over 20,000 clinic visits in 2020, +100% year-over-year $1.85M in fiscal Q3 revenue, +43% quarter-over-quarter Forecasted to increase patient volume from 20,000 clinic visits recorded in 2020 to approximately 65,000 clinic visits in 2021, +225% year-over-year Planning a multistate clinic footprint in 2021, via organic growth and M&A The company recently announced receipt of DEA Licenses for Psilocybin Research. Novamind’s Chief Medical Officer says it best, "Obtaining the DEA Licenses is a critical step towards hosting clinical trials for psilocybin-assisted psychotherapy," commented Dr. Robison. "We're proud of our clinical research organization's track record investigating innovative solutions for central nervous system conditions. This milestone reflects our expertise and enables us to continue on our mission to create breakthroughs in mental health treatment." Why Psilocybin? Psilocybin has shown significant positive outcomes for people with major depressive disorder and for reducing anxiety and depression in people with life-threatening cancer. But wait, that’s not all. Novamind also launched a new Psychedelic Palliative Care Program at its recently opened clinic and research site in Murray, Utah. Among the first-of-its-kind, the Palliative Program combines psychedelic medicine with psychotherapy, workshops, multi-day immersive retreats and group support for palliative care patients and families who are coping with chronic and serious illness. Sit back, relax and watch this powerful interview with Dr. Robison, Chief Medical Officer of Novamind.